Last June, the Supreme Court ruled in Michigan vs. EPA that the EPA had not conducted a sufficient cost-benefit analysis of the 2012 rule, which prohibits the emission of mercury, arsenic and other airborne toxins.
Proxy access was bitterly opposed by public companies and blocked by the United States Court of Appeals for the District of Columbia on controversial grounds, namely that the S.E.C. had not conducted sufficient cost-benefit analysis of the rule.
The financial industry has sued, saying the agency, among other things, had not conducted sufficient cost-benefit analysis of the tough "position limits" plan, which they say would reduce liquidity and increase volatility.
In qualitative surveys this may not be the case, owing to lack of sufficient information on costs.
Without the provisions of sufficient financial support, the cost to local educational agencies of implementing asbestosresponse actions may have an adverse impact in their educational mission.
As long as power plants of sufficient sizes are considered, cost of expert engineering is not prohibitive to projects.
While animal studies and small scale clinical studies support the potential benefit for cell therapies in wound repair, clinical barriers include a lack of sufficient clinical evidence, high costs, and a lack of standardised delivery techniques [ 83].
Drilling a well involves a higher initial cost than connecting to a public water supply, as well as risks of not finding enough water or water of sufficient quality and ongoing costs to pump the water and maintain the well.
For our client, the lack of sufficient investment in friendly staff (good costs) and the costs of exceeding customers' expectations for clean facilities (bad costs) created a deadly combination of lower margins and lower market share.
However, the lack of sufficient raw material, artemisinin, and the cost associated with the drug's manufacture have limited the supply of ACT to malaria sufferers in the Developing World [ 12].
This schedule was based on evidence of sufficient immunogenicity with 2 primary doses, cost savings afforded by a 2- rather than 3-dose primary series, data indicating waning efficacy without a booster dose in HIV-infected children (approximately 4% of South African children <5 years in 2009), and the need to deliver the primary and the booster doses at the youngest possible ages [ 12– 12].
